WO2021066612A3 - 종양 표적화 단백질 또는 이의 단편 및 그것에 결합하는 항체 및 이의 용도 - Google Patents

종양 표적화 단백질 또는 이의 단편 및 그것에 결합하는 항체 및 이의 용도 Download PDF

Info

Publication number
WO2021066612A3
WO2021066612A3 PCT/KR2020/013485 KR2020013485W WO2021066612A3 WO 2021066612 A3 WO2021066612 A3 WO 2021066612A3 KR 2020013485 W KR2020013485 W KR 2020013485W WO 2021066612 A3 WO2021066612 A3 WO 2021066612A3
Authority
WO
WIPO (PCT)
Prior art keywords
fragment
protein
antibody binding
present
tumor
Prior art date
Application number
PCT/KR2020/013485
Other languages
English (en)
French (fr)
Other versions
WO2021066612A2 (ko
Inventor
황태호
조몽
조은아
Original Assignee
주식회사 바이오녹스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 바이오녹스 filed Critical 주식회사 바이오녹스
Priority to JP2022511267A priority Critical patent/JP7456584B2/ja
Priority to AU2020361337A priority patent/AU2020361337A1/en
Priority to EP20871186.1A priority patent/EP4043482A4/en
Priority to CA3156346A priority patent/CA3156346A1/en
Priority to US17/642,868 priority patent/US20220389085A1/en
Priority to CN202080069818.2A priority patent/CN114867738A/zh
Publication of WO2021066612A2 publication Critical patent/WO2021066612A2/ko
Publication of WO2021066612A3 publication Critical patent/WO2021066612A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 종양 표적화 단백질 또는 이의 단편 및 그것에 결합하는 항체 및 이의 용도에 관한 것이다. 보다 상세하게는, 본 발명은 A56 단백질 또는 이의 단편을 코딩하는 핵산을 포함하는 벡터 및 이의 용도에 관한 것이다. 또한, A56 단백질 또는 이의 단편에 결합하는 항체 및 이의 용도에 관한 것이다. 본 발명의 A56 단백질, 이의 단편 또는 이의 변이체를 코딩하는 핵산을 포함하는 벡터는 항암바이러스를 벡터로서 사용하여 개체에 투여할 경우 1차적으로 암세포만을 특이적으로 사멸시킨다. 또한, 항암바이러스에 감염되었음에도 살아남은 암세포는 세포 표면에 A56 단백질을 발현하고 있어 2차 항암치료를 위한 표적화가 가능하다. 따라서, 본 발명의 일 구체예인 A56 단백질 또는 이의 단편을 코딩하는 핵산을 포함하는 벡터 및 A56에 결합하는 항체를 이용할 경우, 암을 효과적으로 치료할 수 있다.
PCT/KR2020/013485 2019-10-02 2020-10-05 종양 표적화 단백질 또는 이의 단편 및 그것에 결합하는 항체 및 이의 용도 WO2021066612A2 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2022511267A JP7456584B2 (ja) 2019-10-02 2020-10-05 腫瘍標的化タンパク質又はその断片、それに結合する抗体及びその使用
AU2020361337A AU2020361337A1 (en) 2019-10-02 2020-10-05 Tumor-targeting protein or fragment thereof, antibody binding thereto and use thereof
EP20871186.1A EP4043482A4 (en) 2019-10-02 2020-10-05 TUMOR TARGETING PROTEIN OR ASSOCIATED FRAGMENT, ANTIBODIES BINDING THEREWITH AND ITS USE
CA3156346A CA3156346A1 (en) 2019-10-02 2020-10-05 PROTEIN TARGETING A TUMOR OR ASSOCIATED FRAGMENT, ANTIBODY BINDING THEREOF AND USE THEREOF
US17/642,868 US20220389085A1 (en) 2019-10-02 2020-10-05 Tumor-targeting protein or fragment thereof, antibody binding thereto and use thereof
CN202080069818.2A CN114867738A (zh) 2019-10-02 2020-10-05 肿瘤靶向蛋白或其片段、与其结合的抗体及其用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190122076 2019-10-02
KR10-2019-0122076 2019-10-02

Publications (2)

Publication Number Publication Date
WO2021066612A2 WO2021066612A2 (ko) 2021-04-08
WO2021066612A3 true WO2021066612A3 (ko) 2021-05-27

Family

ID=75338429

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/013485 WO2021066612A2 (ko) 2019-10-02 2020-10-05 종양 표적화 단백질 또는 이의 단편 및 그것에 결합하는 항체 및 이의 용도

Country Status (8)

Country Link
US (1) US20220389085A1 (ko)
EP (1) EP4043482A4 (ko)
JP (1) JP7456584B2 (ko)
KR (1) KR102550094B1 (ko)
CN (1) CN114867738A (ko)
AU (1) AU2020361337A1 (ko)
CA (1) CA3156346A1 (ko)
WO (1) WO2021066612A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102699872B1 (ko) * 2021-04-29 2024-08-29 주식회사 서지넥스 약물전달물질로서의 대장암 특이적 표적 엑소좀 조성물 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008100292A2 (en) * 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
WO2019106205A1 (en) * 2017-12-01 2019-06-06 Gerd Sutter Immuno-modulated replication-efficient vaccinia virus strain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645456B2 (en) * 2001-04-23 2010-01-12 Sanofi Pasteur Biologics Co. Vaccinia virus strains
WO2011047324A1 (en) 2009-10-16 2011-04-21 The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
PT3445397T (pt) * 2016-04-22 2023-01-13 Vaccinex Inc Exibição de proteína integral de membrana sobre viriões envelopados extracelulares de poxvírus
JP7326663B2 (ja) * 2019-08-26 2023-08-16 バイオノックス インコーポレイテッド がんの処置のための活性成分としてワクシニアウイルス及びヒドロキシ尿素を含む医薬組成物
BR112022004575A2 (pt) * 2019-09-13 2022-08-30 Admare Therapeutics Soc Anticorpos de antígenos de vírus antioncolíticos e métodos de uso dos mesmos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008100292A2 (en) * 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
WO2019106205A1 (en) * 2017-12-01 2019-06-06 Gerd Sutter Immuno-modulated replication-efficient vaccinia virus strain

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B. C. DEHAVEN, K. GUPTA, S. N. ISAACS: "The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins", JOURNAL OF GENERAL VIROLOGY, vol. 92, no. 9, 1 September 2011 (2011-09-01), pages 1971 - 1980, XP055540352, ISSN: 0022-1317, DOI: 10.1099/vir.0.030460-0 *
DATABASE NUCLEOTIDE 18 April 2017 (2017-04-18), ANONYMOUS: "Vaccinia virus isolate Colombia hemagglutinin (HA) gene, complete cds", XP055813602, retrieved from NCBI Database accession no. KU950327 *
DATABASE PROTEIN 28 February 2016 (2016-02-28), ANONYMOUS: "hemagglutinin [Vaccinia virus]", XP055813598, retrieved from NCBI Database accession no. AMK98459 *
MENG, X. ; ZHONG, Y. ; EMBRY, A. ; YAN, B. ; LU, S. ; ZHONG, G. ; XIANG, Y.: "Generation and characterization of a large panel of murine monoclonal antibodies against vaccinia virus", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 409, no. 2, 20 January 2011 (2011-01-20), AMSTERDAM, NL, pages 271 - 279, XP027565802, ISSN: 0042-6822 *

Also Published As

Publication number Publication date
CN114867738A (zh) 2022-08-05
KR20210039973A (ko) 2021-04-12
AU2020361337A1 (en) 2022-03-31
JP2022550667A (ja) 2022-12-05
US20220389085A1 (en) 2022-12-08
EP4043482A2 (en) 2022-08-17
CA3156346A1 (en) 2021-04-08
EP4043482A4 (en) 2024-03-13
JP7456584B2 (ja) 2024-03-27
WO2021066612A2 (ko) 2021-04-08
KR102550094B1 (ko) 2023-07-04

Similar Documents

Publication Publication Date Title
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
WO2018209194A3 (en) Newcastle disease viruses and uses thereof
MX2022006427A (es) "construcciones para terapia génica con microdistrofina y uso de las mismas.
SA520412637B1 (ar) B7 الفيروس الغدي الحال للورم المشفِّر لبروتين
MX2020004578A (es) Composiciones de casz y metodos de uso.
EP4219696A3 (en) Oncolytic virus strain
WO2016196975A8 (en) Neutralizing antibodies to hiv-1 env and their use
WO2011130749A3 (en) Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
MX2019000252A (es) Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos.
WO2016154003A8 (en) Neutralizing antibodies to gp120 and their use
WO2001053506A3 (en) Virus strains for the oncolytic treatment of cancer
MY197423A (en) Recombinant herpes simplex virus and use thereof
WO2005118825A3 (en) Chimeric adenoviruses for use in cancer treatment
WO2008011726A8 (en) Staged immune-response modulation in oncolytic therapy
EA201890796A1 (ru) Новое антитело к мезотелину и содержащая его композиция
WO2009148488A3 (en) Use of oncolytic herpes viruses for killing cancer stem cells
UA91815C2 (ru) Выделенное антитело, которое специфически связывает gdf-8, и его применение
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
IL187321A0 (en) Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2019165122A8 (en) Neutralizing antibodies to hiv-1 env and their use
MX2020010994A (es) Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial.
WO2018017747A3 (en) Oncolytic viruses targeting stat3
WO2019078699A3 (ko) 항-vista 항체 및 이의 용도
WO2021030225A3 (en) Aav capsid variants for targeting human glioblastoma cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20871186

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2022511267

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3156346

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020361337

Country of ref document: AU

Date of ref document: 20201005

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020871186

Country of ref document: EP

Effective date: 20220502